-
Psyence Biomed Launches First Trial Site In Australia For Phase IIb Psilocybin Study In Palliative Care
Monday, September 9, 2024 - 6:02pm | 432Psyence Biomedical Ltd. (NASDAQ:PBM) announced a major milestone on Monday with the initiation of the first clinical trial site in Australia for its Phase IIb study on nature-derived psilocybin as a potential treatment for Adjustment Disorder in patients receiving palliative care. This development...